Exhibit 99.1
| |  |
|---|
| | 5835 Peachtree Corners East, Suite D |
| | Norcross, GA 30092 |
FOR IMMEDIATERELEASE
Guided Therapeutics’ LuViva®Advanced CervicalScan Detected 100% of
Precancers in New Blinded Clinical Study Presented at an International Cervical
Pathology and Colposcopy Conference
LuViva would eliminate nearly half of unnecessary biopsies;
Confirmed earlier studies by detecting more disease than HPV testing
LONDON (May 27,2014)–The LuViva® Advanced Cervical Scan identified 100% of all cervical disease cases in a blinded clinical study presented at the InternationalFederation forCervical PathologyandColposcopy(IFCPC) meeting in London on May 27, 2014. LuViva also correctly identified 44% of women who had a previous abnormal Pap test and who were determined to be false positives as part of the study. LuViva,a non-invasivedeviceusedtodetectcervicaldiseaseinstantlyatthepointofcare,isa product of Guided Therapeutics, Inc. (OTCQB: GTHP) (OTCBB: GTHP).
“This study reinforces not only the superior performance of LuViva, but also highlights the clinical need for point-of-care results to eliminate the high number of unnecessary, painful and costly testing of conventional tissue sample methods such as biopsy,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. “As we introduce LuViva into clinical settings around the world, not only are we positioned to address the tremendous unmet need in developed countries to reduce the high number of false positive results created by conventional testing but we see an even greater opportunity in the developing world to uncover disease where the infrastructure to support conventional, lab-based testing is not available.”
The study, titled “LuViva Cervical Scan as a Triage Test to Reduce Unnecessary Colposcopy and Biopsy,” was conducted on 55 women who had positive Pap tests and were referred to follow up visits with their gynecologist for a colposcopy exam and biopsy. Each subject served as their own control with biopsy being the gold standard for true positive diagnosis.
According to the conclusions of the study: “The high sensitivity, specificity and resulting high negative predictive value of LuViva imply that nearly half of the women currently undergoing colposcopy and biopsy could safely avoid those procedures, thereby improving clinic efficiency and resulting in significant savings to health care systems.”
In the same study, 76% of women tested positive for human papillomavirus (HPV). The HPV testing not only increased the number of false positives, but missed one of the 12 cases of disease correctly identified by LuViva and confirmed by biopsy.
The study was conducted by Dr. James Bentley, Secretary General of the IFCPC and Professor and Division Head of Gynecology Oncology at Dalhousie University School of Medicine in
Halifax, Nova Scotia and Dr. Richard Zane of the Atlanta Women’s Research Institute in Atlanta, Georgia. The study was partially funded by the National Cancer Institute.
About the IFCPC
The International Federation for Cervical Pathology and Colposcopy represents 37 National Pathology and Colposcopy Societies from around the world. The IFCPC’s 15th World Congress will bring together leading scientists, public health experts and policy-makers to translate recent momentous scientific advances into action that will address means to end the epidemic, within the current context of significant global economic challenges. For more information visit: http://ifcpc2014.com.
About LuViva®Advanced Cervical Scan
LuViva isatechnologicallyadvanceddiagnosticdevicethatscansthecervix withlight and uses spectroscopy tomeasure how light interacts with the cervical tissue.Spectroscopy identifies chemical and structural indicators of precancer thatmay bebelow the surface of the cervix ormisdiagnosed as benign.This technique is called biophotonics.Unlike Pap, HPV tests orbiopsies,LuVivadoesnotrequirelaboratory analysisor atissue sample, and is designed to provide resultsimmediately, whicheliminatescostly,painfulandunnecessarytesting. LuVivais designedforusewithwomenwhohaveundergoneinitialscreeningandarecalledbackfor follow-upwithacolposcopyexamination,whichinmanycases,involvestakingabiopsyofthe cervix.ThedeviceisusedinconjunctionwiththeLuViva® CervicalGuidesingle-usepatient interface and calibrationdisposable.
About Guided Therapeutics
Guided Therapeutics,Inc.(OTCBB:GTHP)(OTCQB:GTHP)isthemakerofarapid and painlesstestingplatformbasedonitspatentedbiophotonictechnology that utilizeslight for theearly detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi- center clinicaltrial, with womenat risk for cervical disease,the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics is also developing a non-invasive test for the early detectionof esophageal cancer using the technology platform. For more information, visit:www.guidedinc.com.
TheGuidedTherapeuticsLuViva® Advanced CervicalScan isaninvestigationaldeviceandislimitedby federal lawtoinvestigationaluse.LuViva, thewavelogoand"Early detection, betteroutcomes" areregisteredtrademarks owned by Guided Therapeutics,Inc.
Forward-Looking StatementsDisclaimer: Anumberofthe mattersandsubjectareasdiscussedinthisnewsrelease thatare nothistoricalorcurrent factsdealwithpotentialfuturecircumstancesanddevelopments.The discussion of suchmatters andsubject areasis qualified bytheinherent risks and uncertainties surrounding future expectations generallyand alsomaymaterially differfromGuidedTherapeutics’actual futureexperienceinvolvinganyoformoreofsuch mattersandsubjectareas.Suchrisksand uncertainties includethose relatedtothe earlystageof productsin development, theuncertainty ofmarketacceptanceofproducts, theuncertainty ofdevelopment or effectiveness of distributionchannels,theintense competition inthemedical device industry,the uncertainty of capitaltodevelop products,theuncertainty ofregulatory approval ofproducts, dependenceonlicensed intellectualproperty, aswellasthosethataremore fullydescribed fromtime totimeundertheheading“RiskFactors”in Guided Therapeutics’reports filedwiththe SEC,including GuidedTherapeutics’AnnualReportonForm 10-Kfor the fiscal yearendedDecember 31,2013,andsubsequent quarterlyreports.
Contacts
Bill Wells,GuidedTherapeutics–770-242-8723
Investors: AlisonZiegler,CameronAssociates–212-554-5469
###END###
